Nasdaq
$5.08▼ 0.10%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $225.8MShares out 44.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
3- 10.2After-hours26.10.03 05:158-KKey event#●●●#●●●#●●●
BioAge Labs, Inc.Bullish
BioAge Labs has initiated dosing for the first participant in its Phase 2 'QUELL-DME' trial, evaluating the oral NLRP3 inhibitor BGE-102 for diabetic macular edema. The randomized, three-arm study involves approximately 180 participants over 12 weeks, with topline results expected in the second half of 2027.…more
$5.08-0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.5After-hours26.08.06 06:0010-QEarnings
BioAge Labs, Inc.
BioAge Labs(BIOA)가 2026년 6월 30일로 종료된 분기에 대한 10-Q 분기 보고서를 제출했습니다. 해당 보고서는 노바티스(Novartis Pharma AG)와의 협력 계약 및 재무 상태에 대한 경영진의 인증을 포함하고 있으며, 회사의 재무 보고 및 내부 통제 절차가 적절히 설계 및 운영되고 있음을 확인했습니다.…more
$5.08-0.10%vs prev closeView filingShare - 8.5After-hours26.08.06 05:558-KKey event
BioAge Labs, Inc.
바이오에이지 랩스는 2026년 2분기 순손실 2,610만 달러(주당 0.58달러)를 기록했으며, 6월 30일 기준 현금 및 유가증권 3억 8,130만 달러를 보유하여 2029년까지 운영 자금을 확보했다. 핵심 파이프라인인 BGE-102의 임상 2상(QUELL-CV) 첫 환자 투약을 완료하여 2026년 하반기 탑라인 데이터를 발표할 예정이며, 당뇨병성 황반부종 대상 임상 1b/2a상도 연내 개시할 계획이다.…more
$5.08-0.10%vs prev closeView filingShare
2 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.25After-hours26.09.26 05:30#●●●#●●●
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs announced its participation in upcoming investor conferences, including fireside chats and one-on-one meetings. This announcement is a routine corporate communication and does not contain material financial news.…more
$5.08-0.10%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.8Pre-market26.09.08 21:06
●●●●●●●● ●●●●● ●●●●●●
BioAge Labs has initiated dosing for the first patient in its Phase 2 clinical trial of BGE-102, an oral NLRP3 inhibitor for diabetic macular edema. The study will evaluate the drug's efficacy both as a monotherapy and in combination with standard anti-VEGF treatments in approximately 180 participants.…more
$5.08-0.10%vs prev closeShareBenzinga - 9.2Pre-market26.09.02 21:00
●●●●●●●● ●●●●● ●●●●●●
BioAge Labs announced its participation in several upcoming global healthcare investor conferences throughout September. The company's management will hold fireside chats and one-on-one meetings, though this is a routine investor relations update.…more
$5.08-0.10%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report